Kyungbo Pharmaceutical Selected for Ministry of Trade’s "AI-Based Autonomous Lab Technology Development for Pharmaceutical Manufacturing" Project
Kyungbo Pharmaceutical announced on November 6 that it has been selected as an implementing organization for the "AI-Based Targeted Antibody-Drug Conjugate (ADC) Autonomous Lab Technology Development" project, promoted by the Ministry of Trade, Industry and Energy.
This project aims to enhance the productivity of biopharmaceutical manufacturing and establish a domestic foundation for next-generation antibody-drug conjugate (ADC) development by automating drug design and manufacturing processes through the integration of artificial intelligence (AI) and robotics.
Kyungbo Pharmaceutical, in collaboration with the Korea Institute of Machinery and Materials and Korea University, will conduct research until December 2029. Of the total project development budget of 19.2 billion won, the company will receive 2.4 billion won in research and development funding. Kyungbo Pharmaceutical plans to establish an autonomous laboratory and automated pharmaceutical manufacturing system that integrates AI and robotics. By developing AI-based autonomous manufacturing equipment, the company intends to monitor and control processes in real time, verify pharmaceutical manufacturing stages, and improve the efficiency of prototype production. The strategy is to establish a standardized manufacturing and quality verification system, advance the linker-drug conjugate design and manufacturing system, and accelerate ADC development.
Hot Picks Today
"Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "You Don't Need to Go to the Gym": The Best Exercises for Lowering Hypertension
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
A Kyungbo Pharmaceutical official stated, "Kyungbo Pharmaceutical has positioned the ADC CDMO business as a core growth engine, including a new investment of approximately 85.5 billion won last year to build an ADC GMP production facility. Through this project, we will secure advanced manufacturing capabilities based on AI and robotics, thereby strengthening our competitiveness in the ADC CDMO market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
